Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Empliciti (elotuzumab) for the Treatment of Multiple Myeloma

Drug (Brand / Generic)

Empliciti / elotuzumab

Company / Licensee

Bristol-Myers Squibb (BMS) / AbbVie

Therapy Class

Immunostimulatory antibody

Current Indication

Multiple myeloma

Market Sector

Oncology

Development Status

Approved in the US, MAA under review by EMA
Expand

Go Top